Bristol-Myers Squibb Co. [BMY] moved up 0.04: Why It’s Important

Bristol-Myers Squibb Co. [NYSE: BMY] stock went on an upward path that rose over 0.04% on Friday, amounting to a one-week price decrease of less than -0.22%. The company report on January 20, 2024 at 10:00 AM that Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial.

First presentation of data from the Phase 3 randomized trial shows statistically significant and clinically meaningful improvement in progression-free survival with Opdivo plus Yervoy compared to chemotherapy as first-line treatment in this patient population.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Opdivo plus Yervoy is the first dual immunotherapy regimen to demonstrate significant efficacy benefit compared to chemotherapy as first-line treatment in MSI-H/dMMR mCRC.

Over the last 12 months, BMY stock dropped by -30.54%. The one-year Bristol-Myers Squibb Co. stock forecast points to a potential upside of 17.68. The average equity rating for BMY stock is currently 2.52, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $101.96 billion, with 2.10 billion shares outstanding and 2.03 billion shares in the current float. Compared to the average trading volume of 15.25M shares, BMY stock reached a trading volume of 23075197 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Bristol-Myers Squibb Co. [BMY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $60.87 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.52. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BofA Securities have made an estimate for Bristol-Myers Squibb Co. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 03, 2024.

The Average True Range (ATR) for Bristol-Myers Squibb Co. is set at 1.03, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 2.27. The Price to Book ratio for the last quarter was 3.52, with the Price to Cash per share for the same quarter was set at 3.80. Price to Free Cash Flow for BMY in the course of the last twelve months was 8.72 with Quick ratio for the last quarter at 1.07.

BMY Stock Performance Analysis:

Bristol-Myers Squibb Co. [BMY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.22. With this latest performance, BMY shares dropped by -2.40% in over the last four-week period, additionally sinking by -21.42% over the last 6 months – not to mention a drop of -30.54% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 41.84, with the RSI for the last a single of trading hit 37.27, and the three-weeks RSI is set at 43.23 for Bristol-Myers Squibb Co. [BMY]. The present Moving Average for the last 50 days of trading for this stock 50.71, while it was recorded at 50.10 for the last single week of trading, and 59.59 for the last 200 days.

Insight into Bristol-Myers Squibb Co. Fundamentals:

Bristol-Myers Squibb Co.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.07 and a Current Ratio set at 1.18.


With the latest financial reports released by the company, Bristol-Myers Squibb Co. posted 1.82/share EPS, while the average EPS was predicted by analysts to be reported at 1.72/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 5.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Co. go to -1.01%.

Bristol-Myers Squibb Co. [BMY] Institutonal Ownership Details

The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in BMY stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in BMY stock with ownership which is approximately 5.8325%.